Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostics company Exact Sciences has received a distressing two-star ranking.
With that in mind, let's take a closer look at Exact Sciences and see what CAPS investors are saying about the stock right now.
Madison, Wis. (1995)
CEO Kevin Conroy
CFO Maneesh Arora
Return on Equity (average, past 3 years)
$108.1 million / $2.0 million
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 16% of the All-Star members who have rated Exact Sciences believe the stock will underperform the S&P 500 going forward.
A [$600M] market cap is way too much for unconvincing sensitivity and specificity data that don't provide a convincing basis for widespread adoption of the Cologuard test. Exact is once again a trader's football and I expect the stock to move with the winds until a concrete catalyst emerges.
While you can certainly make quick gains in speculative biotech stocks, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
The article Why Exact Sciences Is Poised to Underperform originally appeared on Fool.com.
Fool contributor Brian Pacampara has no position in any stocks mentioned, and neither does The Motley Fool. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.